Digital World (DWAC) Loses $138.5M of PIPE Investors
by Kristi Marvin on 2022-09-23 at 7:10pm

Digital World (NASDAQ:DWAC) revealed in an 8-K filed this afternoon that $138.5 million worth of investors in their $1 billion PIPE have opted to not participate going forward.

The original $1 billion convertible preferred had an Outside Date of September 20, 2022, at which time any of the PIPE investors could terminate their respective subscription agreements. This leaves $861.5 million currently subscribed, however, remaining investors still have the ability to file termination notices in the future. Today’s 8-k unfortunately did not note which investors have opted to terminate and how many investors that included. We would need to wait for any forthcoming proxy filings to see which remain.

However, what was noted in today’s filing was the following:

“Additionally, as reported in Digital World’s definitive proxy statement dated August 25, 2022, relating to its special meeting of stockholders, currently adjourned to October 10, 2022, it is possible that the parties will restructure the PIPE or renegotiate such arrangements in view of the PIPE closing conditions, evolving market and regulatory conditions.

As shown above, this statement regarding restructuring or renegotiation was also included in the August 25th filing, but it has apparently been included again today for emphasis.  This may or may not be a case of “Chekov’s gun“, but there’s definitely the sound of some bullets rattling around in a chamber somewhere.

As such, FT has already reported that negotiations were purported to be in full swing.  Primarily around the preferred stock conversion price, which gets adjusted if the 10-day VWAP on the share price is below $56. The rumored negotiations involve a new floor conversion price of $2.00, down from the original $10.00.  However, this seems unrealistic from both an TMTG optics viewpoint (Trump will hate it) and from a public SPAC shareholders viewpoint. The impact of dilution from a $2.00 floor would most likely negatively impact the DWAC current share price which has already come down significantly from it’s 52-week high of $175.00.  Today, DWAC closed at $16.50.

Having said that, this deal has had more left turns than a doorknob.  DWAC also has their extension vote on the horizon and it is currently scheduled for October 10th. Keep in mind that TMTG is locked into this deal until at least December 8th. Between now and then, more DWAC news seems highly likely.

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved